B-cell Receptor Activation Induces BIC/miR-155 Expression through a Conserved AP-1 Element

Yin, Qinyan; Wang, Xia; McBride, Jane; Fewell, Claire; Flemington, Erik K.

doi:10.1074/jbc.m708218200

Cited by 210 publications

(222 citation statements)

References 30 publications

Supporting

Mentioning

208

Contrasting

Order By: Relevance

“…This correlation substantiates our findings and provides an insight into the Eμ-miR-155 mouse model, which mostly develops pre-B-cell leukemia but has a B-cell gene expression signature resembling the miR-155 overexpressing human ABC-DLBCL. This is also in line with the role of miR-155 in B-cell activation and its induction with BCR cross-linking (17). Altogether this implies the overlapping molecular signatures from multiple malignancies, which can take different courses.…”

Section: Resultssupporting

confidence: 58%

miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eµ-miR-155 transgenic mouse model

Sandhu

Volinia

Costinean

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

118

View full text Add to dashboard Cite

Multiple studies have established that microRNAs (miRNAs) are involved in the initiation and progression of cancer. Notably, miR-155 is one of the most overexpressed miRNAs in several solid and hematological malignancies. Ectopic miR-155 expression in mice B cells (Eμ-miR-155 transgenic mice) has been shown to induce pre-B-cell proliferation followed by high-grade lymphoma/leukemia. Loss of miR-155 in mice resulted in impaired immunity due to defective T-cell-mediated immune response. Here we provide a mechanistic insight into miR-155-induced leukemogenesis in the Eμ-miR-155 mouse model through genome-wide transcriptome analysis of naïve B cells and target studies. We found that a key transcriptional repressor and proto-oncogene, Bcl6 is significantly down-regulated in Eμ-miR-155 mice. The reduction of Bcl6 subsequently leads to de-repression of some of the known Bcl6 targets like inhibitor of differentiation (Id2), interleukin-6 (IL6), cMyc, Cyclin D1, and Mip1α/ccl3, all of which promote cell survival and proliferation. We show that Bcl6 is indirectly regulated by miR-155 through Mxd1/Mad1 up-regulation. Interestingly, we found that miR-155 directly targets HDAC4, a corepressor partner of BCL6. Furthermore, ectopic expression of HDAC4 in human-activated B-cell-type diffuse large B-cell lymphoma (DLBCL) cells results in reduced miR-155-induced proliferation, clonogenic potential, and increased apoptosis. Meta-analysis of the diffuse large B-cell lymphoma patient microarray data showed that miR-155 expression is inversely correlated with Bcl6 and Hdac4. Hence this study provides a better understanding of how miR-155 causes disruption of the BCL6 transcriptional machinery that leads to up-regulation of the survival and proliferation genes in miR-155-induced leukemias.NfκB | Ingenuity Pathway Analysis M icroRNAs (miRNAs) are 18-24-nucleotide-long noncoding RNA molecules that regulate gene expression in many cellular processes including proliferation, differentiation, and development. Recent studies have established that expression of miRNAs is widely altered in a variety of cancers and miR-155 is one of the most frequently overexpressed miRNAs in various solid and hematological malignancies (1). miR-155 is highly upregulated in Hodgkin, primary mediastinal, and diffuse large B-cell lymphomas (DLBCL) (2, 3) and is almost absent or significantly down-regulated in primary cases of Burkitt lymphoma (4). Overexpression of bic, host mRNA of miR-155, caused increased incidence of leukemia and a decrease in latency of lymphoma development in chickens with elevated levels of MYC (5). Overexpression of miR-155 in mice B cells (Eμ-miR-155) has been shown to cause pre-B-cell leukemia/high-grade lymphoma (6), whereas deletion of bic/miR-155 in mice has been attributed to immunodeficiency and impaired T-cell-dependent antibody response (7,8). Additionally, sustained miR-155 expression in stem cell progenitors induced a myeloproliferative disease in transplanted mice (9). Despite the availability of multiple animal models and a ...

show abstract

Section: Resultssupporting

confidence: 58%

miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eµ-miR-155 transgenic mouse model

Sandhu

Volinia

Costinean

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

118

View full text Add to dashboard Cite

show abstract

“…We further analyzed the effect of IL-10 on transcriptional regulation of the BIC gene through the use of a luciferase reporter plasmid containing 1200 bp of the BIC promoter region (25). In addition, we investigated whether any of the IL-10 effects were mediated through STAT3 by using small interfering RNA (siRNA) targeted against STAT3.…”

Section: Il-10 Inhibits Mir-155 Expression In Response To Tlr4mentioning

confidence: 99%

IL-10 Inhibits miR-155 Induction by Toll-like Receptors

McCoy

Sheedy

Qualls

et al. 2010

Journal of Biological Chemistry

234

180

View full text Add to dashboard Cite

IL-10 is a potent anti-inflammatory cytokine that is crucial for down-regulating pro-inflammatory genes, which are induced by Toll-like receptor (TLR) signaling. In this study, we have examined whether modulation of microRNAs plays a role in the inhibitory effect of IL-10 on TLR4 signaling. Analyzing microRNAs known to be induced by TLR4, we found that IL-10 could inhibit the expression of miR-155 in response to lipopolysaccharide but had no effect on miR-21 or miR-146a. IL-10 inhibited miR-155 transcription from the BIC gene in a STAT3-dependent manner. This inhibitory effect of IL-10 on miR-155 led to an increase in the expression of the miR-155 target, SHIP1. This is the first example of IL-10 playing a role in microRNA function and suggests that through its inhibitory effect on miR-155, IL-10 has the ability to promote anti-inflammatory gene expression.

show abstract

“…The pGL3 reporter construct containing BIC wild type promoter (pGL3-BIC-WT) was a generous gift from Dr Erik Flemington and has previously been described. 53 The STAT5A or STAT5B expression plasmids [wild type, or constitutively active (CA)] were a kind gift from Dr Peter Lobie and have previously been described. 54 Transient transfection with siRNA/miRNA inhibitors (antagomiRs).…”

Section: Chromatin Immunoprecipitation (Chip)mentioning

confidence: 99%